The end of cataract surgery? Experts say vision-robbing condition may soon be treated with DRUGS

A new treatment could pave the way for cataracts to be treated with drugs instead of surgery, research suggests.

Cataracts are cloudy patches on the lens of the eye, which leads to misty vision and blindness for millions worldwide.

Current treatment options for the age-related condition revolve around an operation to remove and replace the affected lens. 

In hope of expanding therapeutic options, Anglia Ruskin University researchers have tested an anti-cataract drug on mice.

Rodents given the compound saw a ‘remarkable difference and improvement’, the researchers said, with nearly half (46 per cent) having reduced cloudiness in their eye. 

Cataracts are when the lens, the small transparent disc inside your eye, develops cloudy patches of protein, leading to vision loss and blindness for millions worldwide. A team of international scientists, led by Professor Barbara Pierscionek at Anglia Ruskin University in London, tested a compound proposed as an anti-cataract drug 

Cataracts are caused by the disorganisation of the proteins in the lens.

This leads to clumps of protein forming that scatter light and severely reduce transmission to the retina.

Professor Barbara Pierscionek and fellow scientists treated mice with cataracts with a compound called VP1-001, which was given through eye drops.

The results, published in the journal Investigative Ophthalmology and Visual Science, show the treatment restored protein organisation of the lens, meaning it could better focus.

The researchers suggest their findings are a significant step towards treating the condition with drugs instead of surgery.

Around 330,000 cataract operation are performed every year in England alone. 

Some 30 per cent of over-65s suffer from cataracts and a tenth have already undergone surgery for the condition.

Half of Americans have cataracts by age 75, rising to 70 per cent by the age of 80. 

Professor Pierscionek, deputy dean of health, education, medicine and social care at the university, said the results show that the proposed anti-cataract drug has ‘positive effects’.

She said: ‘It is the first research of this kind in the world.’

There is a ‘remarkable difference and improvement’ in eyes treated with VP1-001 compared to those which were not, Professor Pierscionek said.

She added: ‘Improvements occurred in some types of cataract but not in all, indicating that this may be a treatment for specific cataracts.

‘This suggests distinctions may need to be made between cataract types when developing anti-cataract medications.

‘It is a significant step forward towards treating this extremely common condition with drugs rather than surgery.’